Esophageal Diseases News - LARVOL Sigma

Esophageal Diseases

Welcome, Profile Billing Logout

104 Mechanisms of Action

«1 2...25 26 27 28 29 303132 33 34 35 36 37 »

||||||||||  pantoprazole / Generic mfg.
Enrollment change:  Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis (clinicaltrials.gov) -  Feb 6, 2013
P3, N=97, Completed,  Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
N=65 --> 97

|||||||||| Trial completion: Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer (clinicaltrials.gov) - Feb 6, 2013
P2, N=110, Completed, Sponsor: Eastern Cooperative Oncology Group
N=65 --> 97 Active, not recruiting --> Completed

||||||||||  alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment closed, Surgery, Metastases:  Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) -  Feb 5, 2013
P2, N=83, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  5-fluorouracil / Generic mfg.
Enrollment change:  Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer (clinicaltrials.gov) -  Feb 4, 2013
P2, N=53, Completed,  Sponsor: University of Chicago
Recruiting --> Active, not recruiting N=40 --> 53

||||||||||  lapatinib / Generic mfg., capecitabine / Generic mfg.
Enrollment closed, Metastases:  GastroLap: Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer (clinicaltrials.gov) -  Feb 4, 2013
P2, N=76, Active, not recruiting,  Sponsor: National Center for Tumor Diseases, Heidelberg
N=40 --> 53 Recruiting --> Active, not recruiting

||||||||||  5-fluorouracil / Generic mfg.
Trial completion:  Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer (clinicaltrials.gov) -  Feb 4, 2013
P2, N=53, Completed,  Sponsor: University of Chicago
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment open: PMSST: The Passy Muir Swallowing Self Training Device (clinicaltrials.gov) - Jan 31, 2013
P=N/A, N=40, Recruiting, Sponsor: James Madison University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Enrollment change: GERD Q NIS: Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=3000, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=2000 --> 3000

|||||||||| Enrollment open: GERD Q NIS: Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=3000, Recruiting, Sponsor: AstraZeneca
N=2000 --> 3000 Not yet recruiting --> Recruiting

||||||||||  oxaliplatin / Generic mfg., gefitinib / Generic mfg.
Trial termination, Metastases:  Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer (clinicaltrials.gov) -  Jan 29, 2013
P1/2, N=0, Terminated,  Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Completed --> Terminated

|||||||||| Clinical: Eosinophilic Gastrointestinal Disorders Patient Registry (clinicaltrials.gov) - Jan 28, 2013
P=N/A, N=1000, Enrolling by invitation, Sponsor: Arkansas Children's Hospital Research Institute

|||||||||| Reflex: Cough Reflex Sensitivity and Bronchial Hyper-responsiveness (clinicaltrials.gov) - Jan 27, 2013
P=N/A, N=36, Recruiting, Sponsor: Mayo Clinic

|||||||||| New P2 trial: Effect of Afferent Oropharyngeal Pharmacological and Electrical Stimulation on Swallow Response and on Activation of Human Cortex in Stroke Patients With Oropharyngeal Dysphagia (clinicaltrials.gov) - Jan 27, 2013
P2, N=200, Recruiting, Sponsor: Hospital de Mataró

||||||||||  lansoprazole / Generic mfg.
New P2 trial:  Lansoprazole in Preterm Infants With Reflux (clinicaltrials.gov) -  Jan 27, 2013
P2, N=5, Completed,  Sponsor: Seoul National University Hospital

||||||||||  omeprazole / Generic mfg.
New P4 trial:  Anti-reflux Control to Decrease Post Tonsillectomy Pain (clinicaltrials.gov) -  Jan 27, 2013
P4, N=140, Active, not recruiting,  Sponsor: Genesys Regional Medical Center

|||||||||| Enrollment change: Swallowing Disorders After Prolonged Mechanical Ventilation (clinicaltrials.gov) - Jan 22, 2013
P=N/A, N=138, Completed, Sponsor: University Hospital, Rouen
Completed --> Terminated N=100 --> 138

|||||||||| Trial completion: Swallowing Disorders After Prolonged Mechanical Ventilation (clinicaltrials.gov) - Jan 22, 2013
P=N/A, N=138, Completed, Sponsor: University Hospital, Rouen
N=100 --> 138 Recruiting --> Completed

|||||||||| Trial completion: Multiple Respiration-Correlated Cone Beam Computed Tomography (CT) Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer (clinicaltrials.gov) - Jan 22, 2013
P1/2, N=16, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  saracatinib (AZD0530) / AstraZeneca
Trial completion, Metastases:  Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer (clinicaltrials.gov) -  Jan 22, 2013
P2, N=35, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Data Bank for Eosinophilic Disorders (clinicaltrials.gov) - Jan 22, 2013
P=N/A, N=500, Completed, Sponsor: Marc Rothenberg
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  MM 111 / Elevation Oncology
New P2 trial, Metastases:  A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach (clinicaltrials.gov) -  Jan 22, 2013
P2, N=120, Recruiting,  Sponsor: Merrimack Pharmaceuticals

||||||||||  arsenic trioxide / Generic mfg.
Trial termination, Metastases:  Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) -  Jan 21, 2013
P2, N=50, Terminated,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Completed --> Terminated; Administratively complete.

|||||||||| Enrollment change, Stroma: Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus (clinicaltrials.gov) - Jan 15, 2013
P1, N=16, Completed, Sponsor: Mayo Clinic
Completed --> Terminated; Administratively complete. N=20 --> 16

||||||||||  aspirin / Generic mfg., esomeprazole / Generic mfg.
Enrollment closed:  Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus (clinicaltrials.gov) -  Jan 15, 2013
P2, N=168, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
N=20 --> 16 Completed --> Active, not recruiting

|||||||||| Trial completion, Stroma: Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus (clinicaltrials.gov) - Jan 15, 2013
P1, N=16, Completed, Sponsor: Mayo Clinic
Completed --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment change: Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=0, Withdrawn, Sponsor: Duke University
Active, not recruiting --> Completed N=10000 --> 0

|||||||||| Trial completion: Effect of Transcutaneous Electrical Stimulation on Post-stroke Dysphagic Patients (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=0, Completed, Sponsor: Hospital de Mataró
N=10000 --> 0 Recruiting --> Completed

||||||||||  Erivedge (vismodegib) / Roche
Enrollment closed, Metastases:  Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) -  Jan 13, 2013
P2, N=116, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting

|||||||||| Clinical: Effect of CCRT on Respiratory Performance and Functional Capacity in Esophagus Cancer Patients (clinicaltrials.gov) - Jan 9, 2013
P=N/A, N=100, Recruiting, Sponsor: Far Eastern Memorial Hospital

|||||||||| Enrollment change, Metastases: A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer (clinicaltrials.gov) - Jan 7, 2013
P2, N=35, Completed, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
Recruiting --> Active, not recruiting N=140 --> 35

||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases:  Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) -  Jan 7, 2013
P1/2, N=43, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
N=140 --> 35 Recruiting --> Active, not recruiting

|||||||||| Trial completion, Metastases: A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer (clinicaltrials.gov) - Jan 7, 2013
P2, N=35, Completed, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment closed: Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain (clinicaltrials.gov) - Jan 6, 2013
P=N/A, N=81, Active, not recruiting, Sponsor: Medical College of Wisconsin
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Vectibix (panitumumab) / Amgen
Trial completion:  Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer (clinicaltrials.gov) -  Jan 6, 2013
P1, N=0, Completed,  Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Clinical: Comparison of O-type Hybrid Knife and IT Knife in ESD (clinicaltrials.gov) - Jan 1, 2013
P=N/A, N=40, Recruiting, Sponsor: Xijing Hospital of Digestive Diseases

|||||||||| Trial completion: Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus (clinicaltrials.gov) - Jan 1, 2013
P1, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  cabazitaxel / Generic mfg.
New P2 trial, Metastases:  Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma (clinicaltrials.gov) -  Dec 26, 2012
P2, N=86, Recruiting,  Sponsor: Weill Medical College of Cornell University

|||||||||| Trial termination: Detection of Minimal Change Esophagitis Using Confocal Laser Endomicroscopy (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=6, Terminated, Sponsor: National University Hospital, Singapore
Active, not recruiting --> Completed Recruiting --> Terminated; Difficulty in recruiting subjects for study

|||||||||| Enrollment change: Detection of Minimal Change Esophagitis Using Confocal Laser Endomicroscopy (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=6, Terminated, Sponsor: National University Hospital, Singapore
Recruiting --> Terminated; Difficulty in recruiting subjects for study N=120 --> 6

||||||||||  oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
P2 data, Enrollment change, Metastases:  Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma (clinicaltrials.gov) -  Dec 20, 2012
P2, N=80, Completed,  Sponsor: National Cancer Institute (NCI)
N=120 --> 6 N=39 --> 80

|||||||||| Enrollment closed: Rubber Band Ligation and Mucosectomy for Gastroesophageal Reflux Disease (GERD) (clinicaltrials.gov) - Dec 20, 2012
P=N/A, N=10, Active, not recruiting, Sponsor: Cook
N=39 --> 80 Recruiting --> Active, not recruiting

|||||||||| Trial completion: Cryotherapy for Barrett's Esophagus and Early Esophageal Cancers (clinicaltrials.gov) - Dec 20, 2012
P0, N=37, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  cisplatin / Generic mfg., docetaxel / Generic mfg.
Biomarker, Trial completion:  PANCHO: p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer (clinicaltrials.gov) -  Dec 19, 2012
P3, N=170, Completed,  Sponsor: Daniela Kandioler
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  imipramine / Generic mfg.
New P3 trial:  Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn (clinicaltrials.gov) -  Dec 18, 2012
P3, N=40, Recruiting,  Sponsor: Mahidol University

||||||||||  imipramine / Generic mfg.
Enrollment open:  Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn (clinicaltrials.gov) -  Dec 18, 2012
P3, N=40, Recruiting,  Sponsor: Mahidol University
Recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Enrollment closed: BENCH: Biology in Patients With Reflux Esophagitis (clinicaltrials.gov) - Dec 18, 2012
P=N/A, N=120, Active, not recruiting, Sponsor: Vanderbilt University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

|||||||||| Trial completion, Metastases: Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Dec 18, 2012
P2, N=38, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  omeprazole / Generic mfg.
Trial withdrawal:  Tongue Exercises and Reflux Therapy for Upper Airway Resistance Syndrome (clinicaltrials.gov) -  Dec 17, 2012
P1, N=0, Withdrawn,  Sponsor: West Side ENT
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn

||||||||||  omeprazole / Generic mfg.
Enrollment change:  Tongue Exercises and Reflux Therapy for Upper Airway Resistance Syndrome (clinicaltrials.gov) -  Dec 17, 2012
P1, N=0, Withdrawn,  Sponsor: West Side ENT
Not yet recruiting --> Withdrawn N=75 --> 0

||||||||||  Revanex (revaprazan) / Yuhan
New P2 trial, P2 data:  Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD) (clinicaltrials.gov) -  Dec 13, 2012
P2, N=150, Active, not recruiting,  Sponsor: Yuhan Corporation